Eurand licenses cyclobenzaprine to Daewoong
This article was originally published in Scrip
Eurandhas licensed its once-daily formulation of the muscle relaxant cyclobenzaprine to Daewoong Pharmaceuticals for development and commercialisation in South Korea. The centrally acting product is used as an adjunct to rest for muscle spasms associated with acute musculoskeletal conditions, and uses Eurand's Diffucaps controlled-release technology. Cephalon markets the product in the US as Amrix.